Sanjiv Patel, Relay CEO
Relay unrolls early data for anti-FGFR drug it thinks stand alone in terms of safety profile
When Third Rock-backed Relay Therapeutics went public last year, it argued its novel drug design platform could potentially break the code in a range of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
